A Phase 2 interventional study of Ruxolitinib in Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF and Post-Essential Thrombocythemia (ET) MF, sponsored by Novartis Pharmaceuticals. Completed at 26 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-09-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 9th largest by enrollment, is one of 2 that started in 2010, is one of 19 in phase 2, and was the 9th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18–75
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 27 · Phase 3 6 · Phase 4 4
First in 2007; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 45 across the 50 interventional studies. Of the 32 that completed or were terminated, 23 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
24 studies in Primary Myelofibrosis by Novartis: 1 open now, 4 under way, 2 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 24 studies in Primary Myelofibrosis by Novartis, this one is the 8th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2010, is one of 5 in phase 2, and was the 6th registered.
Novartis’s Primary Myelofibrosis studies by the year they started, since 2001.
6 of the studies testing ruxolitinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT06345495M.D. Anderson Cancer CenterHigh Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | 2027-01-01 |
| NCT05371964Geron CorporationA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | 2027-02 |
| NCT03069326Memorial Sloan Kettering Cancer CenterA Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, from their registry updates:
Among Novartis’s 24 in Primary Myelofibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study was to determine the efficacy of INC424 as assessed by reduction in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF. The safety and tolerability of INC424 and the effects of INC424 on patient reported outcomes and the duration of response as assessed by reduction in spleen volume was also assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have two or more of the following risk factors:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ruxolitinib was taken twice daily, unless instructed. Starting dose 15 mg BID for patients with baseline platelet count of 100,000/μL to 200,000/μL (inclusive) or 20 mg BID for those with baseline platelet count \>200,000/μL (approximately 12 hours apart: morning and night), increased or decreased per standardized dosing paradigm.
Drug: Ruxolitinib
INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength was 5 mg/tablet INC424 phosphate (free base equivalent).
Also known as: INC424
Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24
The primary measure of spleen size was by MRI. MRIs were performed with a body coil because the objective was to measure organ volume only, not to assess for lesions. MRIs were performed by local radiologists who were instructed not to provide a quantitative measure of spleen volume, but could provide a qualitative assessment such as enlarged, smaller, larger, etc. The scans from an individual patient were to be read by a central reader upon transfer from the site radiologist.
Time frame: 24 weeks
Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Each Scheduled Time Point - Best Response
The best response rate was defined as the proportion of patients achieving a ≥ 35% reduction in spleen volume from baseline at any post-baseline assessment. The best response rate was estimated with an associated 95% confidence interval.
Time frame: Weeks 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240, at any time point
Kaplan Meier Estimates of Duration of Response of at Least ≥ 35% Reduction From Baseline in Spleen Volume Per Kaplan Meier Estimates
For patients who had at least one ≥ 35% reduction in spleen volume from baseline at postbaseline, the duration of response was calculated. The start date of the duration was defined as the first spleen volume measurement that was ≥ 35% reduction from baseline, and the end date of the response duration was defined as the earliest of the following: death, A ≥ 25% increase in spleen volume by MRI (or CT in applicable patients) compared to baseline, Splenic irradiation, Leukemic transformation as defined by a bone marrow or a peripheral blood blast count of ≥ 20%, Splenectomy. Duration of response is calculated only for participants who achieved at least one measured \>= 35% reduction in spleen volume at any time.
Time frame: Weeks 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240
Change in EORTC QLQ-C30 Scores From Baseline in at Week 24
Patient reported outcomes regarding the impact of MF on patients were assessed using the EORTC QLQ-C30. Data from the EORTC QLQ-C30 questionnaire was analyzed using the standardized scores. There were 2 categories to this scale: Functional/QOL scale and Symptom and Other items scale. For each sub-scale, the raw scores were standardized in order to obtain scores ranging from 0 to 100. For Functional/QOL subscales: a higher score represents a higher/better level of functioning. For Symptoms and Other items subscales: a higher score represents worse level of symptoms. The absolute change from baseline was calculated for each scale and summarized descriptively by scheduled visit.
Time frame: Baseline, Week 24
Change in Total Symptom Score From Baseline at Week 24 as Measured by Seven-day Modified MFSAF v2.0
The Seven-day modified MFSAF v2.0 is a 7-item PRO instrument based on the modified MFSAF v2.0 diary administered at specified visits. Symptoms of myelofibrosis (MF) were assessed using this instrument \& included filling up quickly/early satiety, abdominal discomfort, pain under the ribs, night sweats, itching, bone/muscle pain \& inactivity. The first 6 items assessed MF symptom severity at its worst as recalled \& the seventh captured MF-related inactivity in the 7 days prior to the clinic visit assessment. All 7 items asked subjects to record their answers on an 11-point numeric rating scale (NRS) (0=Absent, 10=Worst Imaginable). The first 6 items of the instrument focus on MF symptoms \& are summed to create a Total Symptom score, defined as the sum of the 6 individual symptom scores other than the inactivity score (each with 0-10 point scale) collected on the same week. The total symptom scale ranges from 0 -60 where higher score indicates a worse level of the condition.
Time frame: Baseline, Week 24
A total of 110 patients were planned, 120 patients were enrolled and analyzed.
| Milestone | Ruxolitinib |
|---|---|
| Started | 120 |
| Completed | 52 |
| Not completed | 68 |
| Withdrew: Disease progression | 30 |
| Withdrew: Adverse event | 24 |
| Withdrew: Death | 7 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Protocol violation | 1 |
The primary measure of spleen size was by MRI. MRIs were performed with a body coil because the objective was to measure organ volume only, not to assess for lesions. MRIs were performed by local radiologists who were instructed not to provide a quantitative measure of spleen volume, but could provide a qualitative assessment such as enlarged, smaller, larger, etc. The scans from an individual patient were to be read by a central reader upon transfer from the site radiologist.
| Participants | Ruxolitinib |
|---|---|
| Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24 | 38 |
The best response rate was defined as the proportion of patients achieving a ≥ 35% reduction in spleen volume from baseline at any post-baseline assessment. The best response rate was estimated with an associated 95% confidence interval.
| Percentage of participants | Ruxolitinib |
|---|---|
| Week 24 | 35.8 (27.3 to 44.4) |
| Week 36 | 40.0 (31.2 to 48.8) |
| Week 48 | 44.2 (35.3 to 53.1) |
| Week 72 | 44.2 (35.3 to 53.1) |
| Week 96 | 45.8 (36.9 to 54.7) |
| Week 120 | 45.8 (36.9 to 54.7) |
| Week 144 | 46.7 (37.7 to 55.6) |
| Week 168 | 47.5 (38.6 to 56.4) |
| Week 192 | 47.5 (38.6 to 56.4) |
| Week 216 | 47.5 (38.6 to 56.4) |
| Week 240 | 47.5 (38.6 to 56.4) |
| at any time point | 47.5 (38.6 to 56.4) |
For patients who had at least one ≥ 35% reduction in spleen volume from baseline at postbaseline, the duration of response was calculated. The start date of the duration was defined as the first spleen volume measurement that was ≥ 35% reduction from baseline, and the end date of the response duration was defined as the earliest of the following: death, A ≥ 25% increase in spleen volume by MRI (or CT in applicable patients) compared to baseline, Splenic irradiation, Leukemic transformation as defined by a bone marrow or a peripheral blood blast count of ≥ 20%, Splenectomy. Duration of response is calculated only for participants who achieved at least one measured \>= 35% reduction in spleen volume at any time.
| weeks | Ruxolitinib |
|---|---|
| 12 weeks | 1.00 (1.00 to 1.00) |
| 24 weeks | 0.96 (0.86 to 0.99) |
| 36 weeks | 0.96 (0.86 to 0.99) |
| 48 weeks | 0.93 (0.82 to 0.97) |
| 60 weeks | 0.93 (0.82 to 0.97) |
| 72 weeks | 0.91 (0.79 to 0.96) |
| 84 weeks | 0.89 (0.77 to 0.95) |
| 96 weeks | 0.89 (0.77 to 0.95) |
| 120 weeks | 0.89 (0.77 to 0.95) |
| 144 weeks | 0.85 (0.71 to 0.93) |
| 168 weeks | 0.79 (0.62 to 0.89) |
| 192 weeks | 0.75 (0.57 to 0.86) |
| 216 weeks | 0.75 (0.57 to 0.86) |
| 240 weeks | NA (NA to NA) |
Patient reported outcomes regarding the impact of MF on patients were assessed using the EORTC QLQ-C30. Data from the EORTC QLQ-C30 questionnaire was analyzed using the standardized scores. There were 2 categories to this scale: Functional/QOL scale and Symptom and Other items scale. For each sub-scale, the raw scores were standardized in order to obtain scores ranging from 0 to 100. For Functional/QOL subscales: a higher score represents a higher/better level of functioning. For Symptoms and Other items subscales: a higher score represents worse level of symptoms. The absolute change from baseline was calculated for each scale and summarized descriptively by scheduled visit.
| scores on a scale | Ruxolitinib |
|---|---|
| Func./QOL scales: Global Health Status/QOL | 5.2 ± 22.04 |
| Func./QOL scales: Physical Functioning | 0.6 ± 14.70 |
| Func./QOL scales:Role Functioning | -0.2 ± 21.54 |
| Func./QOL scales: Emotional Functioning | 1.9 ± 14.14 |
| Func./QOL scales: Cognitive Functioning | -4.0 ± 18.43 |
| Func./QOL scales: Social Functioning | 0.2 ± 21.41 |
| Symptom and Other items: Fatigue | -1.3 ± 20.32 |
| Symptom & Other items: Nausea and Vomiting | 0.0 ± 9.43 |
| Symptom and Other items: Pain | -1.8 ± 18.99 |
| Symptom and Other items: Dyspnea | 2.3 ± 25.93 |
| Symptom and Other items: Insomnia | -2.0 ± 30.12 |
| Symptom and Other items: Appetite Loss | -6.3 ± 25.26 |
| Symptom and Other items: Constipation | 4.6 ± 20.02 |
| Symptom and Other items: Diarrhea | 1.7 ± 23.75 |
| Symptom & Other items: Fin. difficulties | -2.0 ± 23.49 |
The Seven-day modified MFSAF v2.0 is a 7-item PRO instrument based on the modified MFSAF v2.0 diary administered at specified visits. Symptoms of myelofibrosis (MF) were assessed using this instrument \& included filling up quickly/early satiety, abdominal discomfort, pain under the ribs, night sweats, itching, bone/muscle pain \& inactivity. The first 6 items assessed MF symptom severity at its worst as recalled \& the seventh captured MF-related inactivity in the 7 days prior to the clinic visit assessment. All 7 items asked subjects to record their answers on an 11-point numeric rating scale (NRS) (0=Absent, 10=Worst Imaginable). The first 6 items of the instrument focus on MF symptoms \& are summed to create a Total Symptom score, defined as the sum of the 6 individual symptom scores other than the inactivity score (each with 0-10 point scale) collected on the same week. The total symptom scale ranges from 0 -60 where higher score indicates a worse level of the condition.
| scores on a scale | Ruxolitinib |
|---|---|
| Change in Total Symptom Score From Baseline at Week 24 as Measured by Seven-day Modified MFSAF v2.0 | -5.0 (-27 to 21) |
Collected over Adverse Events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All Adverse Events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to 240 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib | 13/120 (10.8%) | 60/120 (50%) | 117/120 (97.5%) |
| Event | Ruxolitinib |
|---|---|
| PneumoniaInfections and infestations | 9/120 |
| PyrexiaGeneral disorders | 8/120 |
| Herpes zosterInfections and infestations | 6/120 |
| Lung infectionInfections and infestations | 6/120 |
| AnaemiaBlood and lymphatic system disorders | 5/120 |
| Cardiac failureCardiac disorders | 3/120 |
| BronchitisInfections and infestations | 3/120 |
| GastroenteritisInfections and infestations | 2/120 |
| SepsisInfections and infestations | 2/120 |
| Blood bilirubin increasedInvestigations | 2/120 |
| Event | Ruxolitinib |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 87/120 |
| Platelet count decreasedInvestigations | 44/120 |
| DiarrhoeaGastrointestinal disorders | 42/120 |
| Upper respiratory tract infectionInfections and infestations | 38/120 |
| ThrombocytopeniaBlood and lymphatic system disorders | 34/120 |
| CoughRespiratory, thoracic and mediastinal disorders | 31/120 |
| PyrexiaGeneral disorders | 26/120 |
| Alanine aminotransferase increasedInvestigations | 26/120 |
| Abdominal distensionGastrointestinal disorders | 25/120 |
| NasopharyngitisInfections and infestations | 24/120 |
Full Analysis Set (FAS): comprised of all patients who received at least one dose of ruxolitinib.
| Age, Continuous(Years) | Ruxolitinib |
|---|---|
| Mean | 59.0 ± 12.25 |
| Sex: Female, Male(Participants) | Ruxolitinib |
|---|---|
| Female | 62 |
| Male | 58 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib |
|---|---|
| Japanese | 30 |
| Korean | 17 |
| Chinese | 63 |
| Taiwanese | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Oct 2010 to primary completion in Oct 2017, 84 months.
Results were first posted in Sep 2019, 1 year 10 months after primary completion.
Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 84 months is above that.
Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 32 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib